Xi-Chun Hu - Concepedia

Author

Xi-Chun Hu

Fudan University Shanghai Cancer Center

Also Known As

Xi-Chun Hu, Xi-chun Hu

Publications

685

Citations

H-Index

Concepts

All Affiliations

Fudan University Shanghai Cancer Center Shanghai Medical College of Fudan University Fudan University University of British Columbia Shanghai Jiao Tong University

About

Xi-Chun Hu is an author at Fudan University Shanghai Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	397
2	Health Sciences	1	1	30
3	Cell Biology	1	1	22
4	Immunology	1	1	22
5	Obstetrics	1	1	21

Xi-Chun Hu

Publications

644

Citations

H-Index

Page 1

	Year	Citations
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial Xi-Chun Hu, Jian Zhang, Bing-He Xu, The Lancet Oncology First-line TherapyBreast OncologyOncologyGemcitabine Versus PaclitaxelPharmacology	2015	279
Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer Bi-Yun Wang, Jian Zhang, Jia-Lei Wang, Journal of Experimental & Clinical Cancer Research	2015	177
Primary non-Hodgkin’s lymphoma of the breast: eight-year follow-up experience Hai-Yi Guo, Xin-Min Zhao, Jin Li, International Journal of Hematology Lymphoid NeoplasiaBreast OncologyMedicineSurgical PathologyEight-year Follow-up Experience	2008	45
The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer Jian Zhang, Joseph Ragaz, Ying-Jian Zhang, BMC Cancer	2013	32
Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus Ning-Yi Ma, Xu-Wei Cai, Xiaolong Fu, International Journal of Clinical Oncology Esophageal CancerRadiation TherapySquamous Cell CarcinomaMedicineOncology	2013	30
The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells Lei-Ping Wang, Jun Cao, Jian Zhang, Medical Oncology Tumor BiologySignal TransductionSignaling PathwayCell RegulationCcl2-induced Phosphorylation	2015	22
High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis Chun-Yu Wang, Jiaying Deng, Xu-Wei Cai, Oncotarget	2015	21
A clinical analysis of primary testicular diffuse large B-cell lymphoma in China Bing Cao, Dong-Mei Ji, Xiao-Yan Zhou, Hematology Clinical BehaviorSurgical OncologyCancer ManagementContralateral TestisPathology	2011	21
The SUVmax for 18F-FDG Correlates With Molecular Subtype and Survival of Previously Untreated Metastatic Breast Cancer Jian Zhang, Min Zhou, Joseph Ragaz, Clinical Nuclear Medicine	2013	17

Page 1